Glucose Transport Deficiencies and Neurological Outcomes

Glucose transport deficiencies arise primarily from mutations in the SLC2A1 gene, which encodes the glucose transporter type 1 (GLUT1) protein responsible for ferrying glucose across the blood–brain barrier. Insufficient GLUT1 function deprives neural tissue of its principal energy substrate, precipitating a spectrum of neurological manifestations that includes infantile‐onset seizures, movement disorders, developmental delay and varying degrees of cognitive impairment. Histological and imaging studies reveal that chronic cerebral energy deprivation impairs microvascular development, triggers neuroinflammation and reduces neurotrophic support, thereby compromising neuronal survival and circuit maturation. Clinical management has traditionally centred on dietary interventions that supply alternative fuels, notably ketone bodies, to ameliorate energy failure. Recent advances in molecular genetics, in vivo modelling and metabolic supplementation are converging to refine diagnostic algorithms, stratify phenotypic variability and develop disease‐modifying therapies, including targeted gene delivery and anaplerotic substrates. Given the monogenic aetiology and demonstrable treatment responsiveness, GLUT1 deficiency syndrome serves as a paradigm for understanding broader mechanisms of brain energy failure and for innovating translational strategies with global relevance to neurodegenerative and neurodevelopmental disorders.

Research from Nature Portfolio

Investigations into combined dietary regimens have examined the compatibility of a five-carbon anaplerotic supplement with the classical ketogenic diet in individuals with GLUT1 deficiency. Findings indicate that supplementing with triheptanoin at maximum tolerable doses can modulate ketosis and cerebral fuel metabolism in a subset of patients, informing the development of personalised metabolic therapies. In parallel, preclinical studies employing a viral vector to restore GLUT1 expression in early-symptomatic model organisms have demonstrated that timely repletion of transporter levels averts microvascular deficits, normalises neurotrophic factors and prevents the onset of neurological symptoms. These results underscore the critical window during brain angiogenesis for effective intervention and support gene delivery as a promising disease-modifying approach.

Glucose Transport Deficiencies and Neurological Outcomes publication trend

The graph below shows the total number of articles in glucose transport deficiencies and neurological outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

GLUT1: A facilitative glucose transporter that mediates energy supply to the brain.

SLC2A1: Gene encoding GLUT1; pathogenic variants disrupt cerebral glucose uptake.

Hypoglycorrhachia: Low cerebrospinal fluid glucose concentration indicative of transport impairment.

Ketogenic diet: High-fat, low-carbohydrate regimen that promotes ketone bodies as alternative fuels.

Anaplerotic: Relating to pathways that replenish citric acid cycle intermediates.

Cerebral angiogenesis: Growth of new blood vessels in the brain essential for nutrient delivery.

References

1. Combination of triheptanoin with the ketogenic diet in Glucose transporter type 1 deficiency (G1D). Scientific Reports (2023).
2. Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. Nature Communications (2017).
3. Glucose transporter‐1 deficiency syndrome with extreme phenotypic variability in a five‐generation family carrying a novel SLC2A1 variant. European Journal of Neurology (2024).
4. GLUT1-DS Italian registry: past, present, and future: a useful tool for rare disorders. Orphanet Journal of Rare Diseases (2023).
5. Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open (2020).